Samsung Biologics Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 5.66%

Samsung Biologics Co Ltd (207940) has an Asset Resilience Ratio of 5.66% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 207940 current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

₩1.04 Trillion

≈ $703.39 Million USD Cash + Short-term Investments

Total Assets

₩18.34 Trillion

≈ $12.43 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Samsung Biologics Co Ltd's Asset Resilience Ratio has changed over time. See shareholders equity of Samsung Biologics Co Ltd for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Samsung Biologics Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 207940 company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩1.04 Trillion	5.66%
Total Liquid Assets	₩1.04 Trillion	5.66%

Asset Resilience Insights

Limited Liquidity: Samsung Biologics Co Ltd maintains only 5.66% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Samsung Biologics Co Ltd Industry Peers by Asset Resilience Ratio

Compare Samsung Biologics Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Argen-X F:1AE	Biotechnology	25.67%
Tubize-Fin BR:TUB	Biotechnology	0.05%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
Dashenlin Pharm Grp Co Ltd SHG:603233	Biotechnology	0.02%
Staidson Beijing Biopharma SHE:300204	Biotechnology	7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	41.25%
Ardelyx Inc NASDAQ:ARDX	Biotechnology	41.14%
Xiangxue Pharmaceutical SHE:300147	Biotechnology	0.05%

Annual Asset Resilience Ratio for Samsung Biologics Co Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Samsung Biologics Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	5.42%	₩940.07 Billion ≈ $637.07 Million	₩17.34 Trillion ≈ $11.75 Billion	-5.10pp
2023-12-31	10.52%	₩1.69 Trillion ≈ $1.14 Billion	₩16.05 Trillion ≈ $10.87 Billion	-3.37pp
2022-12-31	13.89%	₩2.30 Trillion ≈ $1.56 Billion	₩16.58 Trillion ≈ $11.24 Billion	-2.73pp
2021-12-31	16.61%	₩1.32 Trillion ≈ $897.27 Million	₩7.97 Trillion ≈ $5.40 Billion	+3.79pp
2020-12-31	12.82%	₩823.60 Billion ≈ $558.14 Million	₩6.42 Trillion ≈ $4.35 Billion	+3.27pp
2019-12-31	9.55%	₩564.82 Billion ≈ $382.77 Million	₩5.91 Trillion ≈ $4.01 Billion	-9.02pp
2018-12-31	18.58%	₩1.11 Trillion ≈ $752.88 Million	₩5.98 Trillion ≈ $4.05 Billion	+18.26pp
2017-12-31	0.31%	₩22.61 Billion ≈ $15.32 Million	₩7.18 Trillion ≈ $4.87 Billion	-12.78pp
2016-12-31	13.09%	₩986.29 Billion ≈ $668.39 Million	₩7.53 Trillion ≈ $5.11 Billion	--

pp = percentage points

About Samsung Biologics Co Ltd

KO:207940 Korea Biotechnology

Market Cap

$31.37 Billion

₩46.29 Trillion KRW

Market Cap Rank

#842 Global

#16 in Korea

Share Price

₩1000000.00

Change (1 day)

+0.00%

52-Week Range

₩991000.00 - ₩1000000.00

All Time High

₩1000000.00